The blockbuster drug era is over and drug manufacturers are now striving for a more diversified portfolio by targeting a greater number of monoclonal antibody (mAb) products at lower production volumes. Major changes to the landscape of today’s industry are creating higher demands for flexible solutions that can minimize changeover time between campaigns. With a newer toolbox of options to intensify downstream manufacturing operations, it is important to understand what factors should impact your decision.
Click here to read the article.